- Home
- PYPD vs RVPH Comparison
PYPD vs RVPH Comparison
Compare PYPD & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- RVPH
- Stock Information
- Founded
- PYPD 2008
- RVPH 2006
- Country
- PYPD Israel
- RVPH United States
- Employees
- PYPD N/A
- RVPH N/A
- Industry
- PYPD Medical/Dental Instruments
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- RVPH Health Care
- Exchange
- PYPD Nasdaq
- RVPH Nasdaq
- Market Cap
- PYPD 35.3M
- RVPH 31.5M
- IPO Year
- PYPD 2020
- RVPH N/A
- Fundamental
- Price
- PYPD $3.58
- RVPH $0.36
- Analyst Decision
- PYPD Strong Buy
- RVPH Strong Buy
- Analyst Count
- PYPD 5
- RVPH 5
- Target Price
- PYPD $11.40
- RVPH $9.00
- AVG Volume (30 Days)
- PYPD 1.4M
- RVPH 1.7M
- Earning Date
- PYPD 08-13-2025
- RVPH 08-13-2025
- Dividend Yield
- PYPD N/A
- RVPH N/A
- EPS Growth
- PYPD N/A
- RVPH N/A
- EPS
- PYPD N/A
- RVPH N/A
- Revenue
- PYPD N/A
- RVPH N/A
- Revenue This Year
- PYPD N/A
- RVPH N/A
- Revenue Next Year
- PYPD N/A
- RVPH N/A
- P/E Ratio
- PYPD N/A
- RVPH N/A
- Revenue Growth
- PYPD N/A
- RVPH N/A
- 52 Week Low
- PYPD $2.30
- RVPH $0.30
- 52 Week High
- PYPD $4.49
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- PYPD 59.00
- RVPH 27.45
- Support Level
- PYPD $3.12
- RVPH $0.72
- Resistance Level
- PYPD $3.75
- RVPH $0.83
- Average True Range (ATR)
- PYPD 0.29
- RVPH 0.07
- MACD
- PYPD 0.01
- RVPH -0.03
- Stochastic Oscillator
- PYPD 69.83
- RVPH 9.67
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.